Regeneron Pharmaceuticals Inc (REGN) - News Archive

Showing 11 of 51 results.

Regeneron Showcases Novel Investigational Treatments for Solid Tumors and Blood Cancers, Holds Promise for Advancing Cancer Care.

Regeneron Showcases Progress in Advancing Novel Investigational Treatment Approaches for Solid Tumors and Blood Cancers at ASCORegeneron Pharmaceuticals, a leading biotechnology company, has recently announced significa...

Apr 24, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Regeneron's Genetic Medicine Research offers Hope for Hearing Restoration in Profoundly Deaf Children: Updated Findings to be Presented at ASGCT Conference

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)Regeneron Pharmaceuticals, a leading biotechnology company, is set to showcase its groundbreaking research...

Apr 22, 2024 • Major Pharmaceutical Preparations Industry Announcement

Regeneron's Odronextamab Faces Regulatory Hurdles as FDA Issues Complete Response Letters, Enrollment Status of Confirmatory Trials the Primary Concern

Regeneron Faces Regulatory Hurdles for Odronextamab, Potential Treatment for LymphomasTARRYTOWN, N.Y., March 25, 2024 - Pharmaceutical company Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has provided an update on its...

Mar 25, 2024 • Major Pharmaceutical Preparations Industry Management Announcement

FDA Approves Praluent for Treating Genetic High Cholesterol in Children, While New Data Shows Encouraging Efficacy in Treating Follicular and Diffuse Large B-cell Lymphomas

In a significant development, the US Food and Drug Administration (FDA) has expanded its approval of Praluent (alirocumab) injection to include children aged 8 years and older who suffer from heterozygous familial hyper...

Mar 11, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

EYLEA HD Bolsters Treatment of Sight-Threatening Conditions, While Dupixent's Approval in Japan Offers a Ray of Hope for Chronic Itching Patients

EYLEA HD: A Breakthrough in the Treatment of Age-related Macular Degeneration and Diabetic Macular Edema, and Japan s Groundbreaking Approval of Dupixent for Chronic Spontaneous Urticaria In a groundbreaking development...

Mar 8, 2024 • Major Pharmaceutical Preparations Industry Product Service News

Dupixent (Dupilumab) SBLA Accepted for FDA Priority Review for COPD with Type 2 Inflammation: A Potential Breakthrough in COPD Treatment

is pleased to present the following article, which provides an overview of the recently accepted supplemental Biologics License Application (sBLA) for Dupixent (Dupilumab) by the U.S. Food and Drug Administration (FDA)....

Feb 23, 2024 • Major Pharmaceutical Preparations Industry Product Service News Biotech

Advancing Treatment Possibilities: Linvoseltamab's BLA for Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

In a promising development, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently announced the acceptance of the Biologics License Application (BLA) for linvoseltamab by the U.S. Food and Drug Administration (FDA) fo...

Feb 21, 2024 • Major Pharmaceutical Preparations Industry Clinical Study

Dupixent Breaks Ground as Japan Approves World's First Treatment for Chronic Spontaneous Urticaria, Offering Relief and Hope for Sufferers

Japan First in the World to Approve Dupixent (dupilumab) for Chronic Spontaneous Urticaria (CSU)Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo.In a significa...

Feb 16, 2024 • Major Pharmaceutical Preparations Industry Product Service News Regeneron

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

Regeneron Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, recently announced its acquisition of 2seventy bios preclinical and clinical stage cell therapy pipeline. The deal grants Regeneron full develo...

Jan 30, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition Regeneron

Pioneering Research Reveals Potential of Odronextamab and ctDNA in Long-term Prognostication of Diffuse Large B-cell Lymphoma

In an era marked with significant strides in cancer research, groundbreaking data from leading medical trials have unfolded promising potential in the fight against diffuse large B-cell lymphoma (DLBCL). As part of the...

Dec 10, 2023 • Major Pharmaceutical Preparations Industry Clinical Study

Revolutionizing Oncology: Regeneron's Groundbreaking Combination Therapies Show Promise in Ovarian Cancer Treatment while Navigating Financial Challenges

Integrating Cutting-Edge Therapies: Regeneron s Promising Advances in OncologyRegeneron Pharmaceuticals Inc., a renowned biotechnology company, has recently shared significant progress in its novel combination therapies...

Dec 7, 2023 Clinical Study